Peter de Waele
Chief Executive Officer at Advanced Therapies Consulting Limited
Peter de Waele active positions
| Companies | Position | Start | End |
|---|---|---|---|
| Advanced Therapies Consulting Limited | Chief Executive Officer | - | - |
Career history of Peter de Waele
Former positions of Peter de Waele
| Companies | Position | Start | End |
|---|---|---|---|
| CELYAD ONCOLOGY SA | Chief Tech/Sci/R&D Officer | 2010-10-31 | - |
| Corporate Officer/Principal | 2010-10-31 | - | |
| Xcellentis NV | Chief Operating Officer | 2005-12-31 | 2005-12-31 |
| Founder | 2005-12-31 | 2005-12-31 | |
| Ghent University | Corporate Officer/Principal | 1985-12-31 | 1985-12-31 |
Fujirebio Europe NV
 Fujirebio Europe NV Medical SpecialtiesHealth Technology Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium. | Corporate Officer/Principal | - | - |
Training of Peter de Waele
| Ghent University | Doctorate Degree |
Statistics
International
| Belgium | 5 |
| United Kingdom | 2 |
Operational
| Corporate Officer/Principal | 3 |
| Chief Tech/Sci/R&D Officer | 1 |
| Chief Operating Officer | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| CELYAD ONCOLOGY SA | Health Technology |
| Private companies | 3 |
|---|---|
| Xcellentis NV | Health Technology |
Fujirebio Europe NV
Fujirebio Europe NV Medical SpecialtiesHealth Technology Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium. | Health Technology |
| Advanced Therapies Consulting Limited |
- Stock Market
- Insiders
- Peter de Waele
- Experience
